Literature DB >> 32297065

The role and molecular mechanism of epigenetics in cardiac hypertrophy.

Hao Lei1, Jiahui Hu1, Kaijun Sun1, Danyan Xu2.   

Abstract

Cardiac hypertrophy is a significant risk factor for cardiovascular disease, including heart failure, arrhythmia, and sudden death. Cardiac hypertrophy involves both embryonic gene expression and transcriptional reprogramming, which are tightly regulated by epigenetic mechanisms. An increasing number of studies have demonstrated that epigenetics plays an influential role in the occurrence and development of cardiac hypertrophy. Here, we summarize the latest research progress on epigenetics in cardiac hypertrophy involving DNA methylation, histone modification, and non-coding RNA, to help understand the mechanism of epigenetics in cardiac hypertrophy. The expression of both embryonic and functional genes can be precisely regulated by epigenetic mechanisms during cardiac hypertrophy, providing a substantial number of therapeutic targets. Thus, epigenetic treatment is expected to become a novel therapeutic strategy for cardiac hypertrophy. According to the research performed to date, epigenetic mechanisms associated with cardiac hypertrophy remain far from completely understood. Therefore, epigenetic mechanisms require further exploration to improve the prevention, diagnosis, and treatment of cardiac hypertrophy.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acetylation; Cardiac hypertrophy; Epigenetics; Methylation; Non-coding RNA

Mesh:

Year:  2021        PMID: 32297065     DOI: 10.1007/s10741-020-09959-3

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  93 in total

Review 1.  The emerging role of epigenetics in pulmonary hypertension.

Authors:  Elisabetta Gamen; Werner Seeger; Soni Savai Pullamsetti
Journal:  Eur Respir J       Date:  2016-08-04       Impact factor: 16.671

Review 2.  Epigenetic Changes in Diabetes and Cardiovascular Risk.

Authors:  Samuel T Keating; Jorge Plutzky; Assam El-Osta
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

3.  DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.

Authors:  M Okano; D W Bell; D A Haber; E Li
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 4.  Epigenetics of Atherosclerosis: Emerging Mechanisms and Methods.

Authors:  Nadiya Khyzha; Azad Alizada; Michael D Wilson; Jason E Fish
Journal:  Trends Mol Med       Date:  2017-03-11       Impact factor: 11.951

Review 5.  The alpha1-adrenergic receptors in cardiac hypertrophy: signaling mechanisms and functional implications.

Authors:  Susanna Cotecchia; Cosmo Damiano Del Vescovo; Matilde Colella; Stefania Caso; Dario Diviani
Journal:  Cell Signal       Date:  2015-07-10       Impact factor: 4.315

6.  Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.

Authors:  Chun Li Zhang; Timothy A McKinsey; Shurong Chang; Christopher L Antos; Joseph A Hill; Eric N Olson
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

7.  MicroRNA-133 controls cardiac hypertrophy.

Authors:  Alessandra Carè; Daniele Catalucci; Federica Felicetti; Désirée Bonci; Antonio Addario; Paolo Gallo; Marie-Louise Bang; Patrizia Segnalini; Yusu Gu; Nancy D Dalton; Leonardo Elia; Michael V G Latronico; Morten Høydal; Camillo Autore; Matteo A Russo; Gerald W Dorn; Oyvind Ellingsen; Pilar Ruiz-Lozano; Kirk L Peterson; Carlo M Croce; Cesare Peschle; Gianluigi Condorelli
Journal:  Nat Med       Date:  2007-04-29       Impact factor: 53.440

Review 8.  Hypertrophy of the heart: a new therapeutic target?

Authors:  Norbert Frey; Hugo A Katus; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2004-04-06       Impact factor: 29.690

Review 9.  Epigenetic Mechanisms of Longevity and Aging.

Authors:  Payel Sen; Parisha P Shah; Raffaella Nativio; Shelley L Berger
Journal:  Cell       Date:  2016-08-11       Impact factor: 41.582

10.  Charting a dynamic DNA methylation landscape of the human genome.

Authors:  Michael J Ziller; Hongcang Gu; Fabian Müller; Julie Donaghey; Linus T-Y Tsai; Oliver Kohlbacher; Philip L De Jager; Evan D Rosen; David A Bennett; Bradley E Bernstein; Andreas Gnirke; Alexander Meissner
Journal:  Nature       Date:  2013-08-07       Impact factor: 49.962

View more
  13 in total

1.  MALAT1 regulates hypertrophy of cardiomyocytes by modulating the miR-181a/HMGB2 pathway.

Authors:  Feng Chen; Wenfeng Li; Dandan Zhang; Youlin Fu; Wenjin Yuan; Gang Luo; Fuwei Liu; Jun Luo
Journal:  Eur J Histochem       Date:  2022-06-21       Impact factor: 1.966

2.  Identification of a Hydrogen-Sulfide-Releasing Isochroman-4-One Hybrid as a Cardioprotective Candidate for the Treatment of Cardiac Hypertrophy.

Authors:  Yu Wang; Yuechen Liu; Hongyu Wu; Shengtao Xu; Fenfen Ma
Journal:  Molecules       Date:  2022-06-27       Impact factor: 4.927

3.  Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways.

Authors:  Dan Li; Ying-Ying Guo; Xian-Feng Cen; Hong-Liang Qiu; Si Chen; Xiao-Feng Zeng; Qian Zeng; Man Xu; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2021-12-16       Impact factor: 7.169

4.  Abnormalities in lysine degradation are involved in early cardiomyocyte hypertrophy development in pressure-overloaded rats.

Authors:  Jialing Liu; Junhao Hu; Lanlan Tan; Qi Zhou; Xiaojing Wu
Journal:  BMC Cardiovasc Disord       Date:  2021-08-21       Impact factor: 2.298

5.  Different activation of MAPKs and Akt/GSK3β after preload vs. afterload elevation.

Authors:  Nico Hartmann; Lena Preuß; Belal A Mohamed; Moritz Schnelle; Andre Renner; Gerd Hasenfuß; Karl Toischer
Journal:  ESC Heart Fail       Date:  2022-03-21

Review 6.  Circular RNAs in Sudden Cardiac Death Related Diseases: Novel Biomarker for Clinical and Forensic Diagnosis.

Authors:  Meihui Tian; Zhipeng Cao; Hao Pang
Journal:  Molecules       Date:  2021-02-21       Impact factor: 4.411

7.  Liquiritin Attenuates Angiotensin II-Induced Cardiomyocyte Hypertrophy via ATE1/TAK1-JNK1/2 Pathway.

Authors:  Jiajia Mo; Peng Zhou; Zhaoxing Chu; Yan Zhao; Xiang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-16       Impact factor: 2.629

8.  Deubiquitinase Ubiquitin-Specific Protease 10 Deficiency Regulates Sirt6 signaling and Exacerbates Cardiac Hypertrophy.

Authors:  Dian-Hong Zhang; Jie-Lei Zhang; Zhen Huang; Lei-Ming Wu; Zhong-Min Wang; Ya-Peng Li; Xin-Yu Tian; Ling-Yao Kong; Rui Yao; Yan-Zhou Zhang
Journal:  J Am Heart Assoc       Date:  2020-11-10       Impact factor: 5.501

Review 9.  The role and molecular mechanism of FoxO1 in mediating cardiac hypertrophy.

Authors:  Wei Yu; Chunjuan Chen; Jidong Cheng
Journal:  ESC Heart Fail       Date:  2020-10-22

10.  Spironolactone Inhibits Cardiomyocyte Hypertrophy by Regulating the Ca2+/Calcineurin/p-NFATc3 Pathway.

Authors:  Xin Wang; Wenting Zhang; Jingtao Na; Yanping Huo; Yacheng Wang; Ketong Liu
Journal:  J Healthc Eng       Date:  2021-12-16       Impact factor: 2.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.